MET and hepatocellular carcinoma: Cabozantinib, a multi-kinase inhibitor against VEGF receptors 1-3, c-Met, and the TAM receptors (TYRO3, AXL, MER) family, has been approved for advanced HCC patients who are resistant to sorafenib (62).